Reclast (zoledronic acid) Order Form

<table>
<thead>
<tr>
<th>Date &amp; Time</th>
<th>Pharmacy is not permitted to dispense this medication until the order form is completed and signed.</th>
</tr>
</thead>
</table>
|             | Diagnosis:  

- Paget’s disease
- Treatment and prevention of glucocorticoid-induced osteoporosis in patients expected to be on glucocorticoids for at least 12 months
- Senile Osteoporosis (additional criteria required – see below)

In order for Reclast (zoledronic acid) to be dispensed for senile osteoporosis, the patient must fall into one of two categories **(please select one):**

- post-menopausal woman
- man age 50 or older

**Contraindications:**
- Hypocalcemia
- Patients with creatinine clearance < 35 ml/min and in those with evidence of acute renal impairment
- Hypersensitivity to any component of Reclast

In addition, in order for Reclast (zoledronic acid) to be dispensed for senile osteoporosis, at least one condition from **EACH SECTION** below must be met:

**Section 1 (Osteoporosis foundation):**

- A hip or vertebral (clinical or morphometric) fracture
- Other prior fractures and low bone mass (T-score between -1.0 and -2.5 at the femoral neck, total hip or spine)
- T-score less than -2.5 at femoral neck, total hip or spine after appropriate evaluation to exclude secondary causes
- Low bone mass (T-score -1.0 to -2.5 at femoral neck, total hip or spine) and secondary causes associated with high risk of fracture (such as glucocorticoid use or total immobilization)
- Low bone mass (T-score between -1.0 to -2.5 at femoral neck, hip or spine) with a 10-year probability of hip fracture > 3% or 10-year probability of any major osteoporosis-related fracture of > 20% based on the US-adapted WHO algorithm

**Section 2 Criteria:**

- Documented allergy to shellfish and/or salmon derivatives
- Documented intolerance of oral bisphosphonate therapy due to medical or surgical conditions including but not limited to:
  - [ ] severe esophageal disease (e.g. ulcerations, strictures)
  - [ ] esophageal symptoms or dysphagia severe enough to cause patient non-compliance with oral bisphosphonates
  - [ ] inability to take anything by mouth
  - [ ] inability to sit or stand for at least 30 minutes
  - [ ] intestinal malabsorption
  - [ ] other
- Documented non-compliance with oral bisphosphonate treatment regimen of at least three months
### Labs: The following labs must be resulted and available within last 30 days:
- BUN/Creatinine
- Albumin
- Calculated Creatinine Clearance greater than or equal to 35 mL/min (as calculated by Crokoft-Gault equation)
- Serum Calcium within normal range
- 25-OH Vitamin D level

If above labs have not been done within last 30 days the Infusion Center will draw on day of infusion.

**Obtain peripheral IV access**

**Give Sodium Chloride 0.9% 250 mL IV over 30 minutes prior to AND post infusion of Zoledronic Acid (RECLAST)**

**Premedicate 30 minutes prior to infusion with the following for the prevention of hypersensitivity/allergic reaction:**
- Benadryl (diphenhydramine) 25 mg PO once
- Benadryl (diphenhydramine) 50 mg PO once
- Tylenol (acetaminophen) 325 mg two tabs PO once
- Tylenol ES (acetaminophen) 500 mg two tabs PO once
- Claritin (loratadine) 10 mg PO once
- Other: _________________________

**Infuse Reclast (zoledronic acid) 5mg IV over 30 minutes**

If patient experiences an adverse drug reaction, such as but not limited to urticaria, anaphylaxis or hypotension (SBP drop by 20 mmHg from baseline), stop infusion and call physician

**Date** / **Time**  
**Physician Signature**